logo
500257 logo

Lupin Community

BSE:500257 Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

500257 logo
Lupin
AN
AnalystConsensusTarget
Consensus Narrative from 36 Analysts

Launching Injectable Products Like Liraglutide Will Strengthen Future Prospects

Key Takeaways Lupin's focus on complex injectables, respiratory products, and biosimilars is set to boost margins and diversify revenue streams. Strategic acquisitions and ANDA filings aim to enhance revenue and earnings growth through an enriched product portfolio.
View narrative
₹2.27k
FV
14.3% undervalued intrinsic discount
6.05%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
3 days ago author updated this narrative